Cardiology · Calcium Channel BlockerRegulatory Approvalregulatorymid-term

FDA Approval Letter for Verapamil Hydrochloride ANDA078306

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:31:12 AM

Assessment confidence: 48% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Verapamil Hydrochloride under ANDA078306 is a significant regulatory milestone that could strengthen RISING's position in the cardiology market. This development necessitates close monitoring of competitive dynamics and market entry strategies from other players in the calcium channel blocker segment. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 7 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for Verapamil Hydrochloride and consider strategic positioning against other calcium channel blockers. The strongest clinical anchor is Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In cardiology, 6 regulatory and 1 competitive items passed relevance filtering for Verapamil Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This approval may enhance RISING's market position in the cardiology segment, potentially impacting competitors in the calcium channel blocker space.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The approval signifies compliance with FDA standards, which may influence future submissions and approvals in the cardiology therapeutic area.

Key Risks

Elevated medium regulatory exposure for Verapamil Hydrochloride could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Verapamil Hydrochloride through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The approval could lead to increased market share for RISING, impacting revenue streams and competitive positioning against other calcium channel blockers.
Upside for Verapamil Hydrochloride may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Portfolio teams should assess the competitive landscape for Verapamil Hydrochloride and consider strategic positioning against other calcium channel blockers.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent competitive responses from other manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from Dutch societal perspective.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Verapamil Hydrochloride

Commercial impact

medium

The approval could lead to increased market share for RISING, impacting revenue streams and competitive positioning against other calcium channel blockers.

Regulatory impact

medium

The approval signifies compliance with FDA standards, which may influence future submissions and approvals in the cardiology therapeutic area.

What to watch

Monitor market entry timelines and any subsequent competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.